Cogent Biosciences (COGT) Liabilities and Shareholders Equity (2017 - 2026)

Cogent Biosciences' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $903.0 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 218.19% year-over-year to $903.0 million; the TTM figure through Mar 2026 stood at $2.5 billion (up 78.26% YoY), while the FY2025 annual figure was $937.6 million, up 185.94% from the prior year.
• Liabilities and Shareholders Equity was $903.0 million for Q1 2026 at Cogent Biosciences, down from $937.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $937.6 million in Q4 2025 to a low of $206.9 million in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $410.2 million across 5 years, with a median of $355.4 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity tumbled 40.39% in 2025, then surged 218.19% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $300.8 million in 2022, then advanced by 4.2% to $313.4 million in 2023, then rose by 4.61% to $327.9 million in 2024, then jumped by 185.94% to $937.6 million in 2025, then dropped by 3.69% to $903.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $903.0 million (Q1 2026), $937.6 million (Q4 2025), and $425.9 million (Q3 2025), per Business Quant data.